Another $VTAE, Vitae Pharmaceuticals Inc (NASD
Post# of 22755
Posted On: 03/14/2016 6:56:48 PM
Another $VTAE,
Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Receives Consensus Recommendation of “Buy” from Brokerages
March 14th, 2016 - By Faye Duncan - 0 comments
Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE) has been given an average rating of “Buy” by the six brokerages that are covering the stock, Market Beat.com reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $21.50.
VTAE has been the topic of a number of recent research reports. Stifel Nicolaus lowered shares of Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 4th. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Vitae Pharmaceuticals in a research note on Friday, December 11th. Piper Jaffray reiterated a “buy” rating and set a $18.00 price objective on shares of Vitae Pharmaceuticals in a research note on Tuesday, December 29th. Wells Fargo started coverage on shares of Vitae Pharmaceuticals in a research note on Thursday, December 3rd. They set an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded shares of Vitae Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 5th.
In other news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The shares were sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total transaction of $290,340.00. The disclosure for this sale can be found here.
An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Candriam Luxembourg S.C.A. purchased a new position in shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 133,000 shares of the company’s stock, valued at approximately $2,407,000. Candriam Luxembourg S.C.A. owned approximately 0.61% of Vitae Pharmaceuticals as of its most recent filing with the SEC.
Vitae Pharmaceuticals (NASDAQ:VTAE) traded up 2.31% during trading on Monday, reaching $4.88. 573,488 shares of the company’s stock were exchanged. The firm’s market cap is $106.73 million. The stock’s 50 day moving average price is $8.57 and its 200 day moving average price is $12.03. Vitae Pharmaceuticals has a 52-week low of $4.15 and a 52-week high of $18.71.
Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.10. The company earned $0.09 million during the quarter, compared to the consensus estimate of $0.14 million. Vitae Pharmaceuticals’s revenue for the quarter was down 42.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) earnings per share. Equities research analysts anticipate that Vitae Pharmaceuticals will post ($2.23) EPS for the current fiscal year.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Receives Consensus Recommendation of “Buy” from Brokerages
March 14th, 2016 - By Faye Duncan - 0 comments
Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE) has been given an average rating of “Buy” by the six brokerages that are covering the stock, Market Beat.com reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $21.50.
VTAE has been the topic of a number of recent research reports. Stifel Nicolaus lowered shares of Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 4th. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Vitae Pharmaceuticals in a research note on Friday, December 11th. Piper Jaffray reiterated a “buy” rating and set a $18.00 price objective on shares of Vitae Pharmaceuticals in a research note on Tuesday, December 29th. Wells Fargo started coverage on shares of Vitae Pharmaceuticals in a research note on Thursday, December 3rd. They set an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded shares of Vitae Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 5th.
In other news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The shares were sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total transaction of $290,340.00. The disclosure for this sale can be found here.
An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Candriam Luxembourg S.C.A. purchased a new position in shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 133,000 shares of the company’s stock, valued at approximately $2,407,000. Candriam Luxembourg S.C.A. owned approximately 0.61% of Vitae Pharmaceuticals as of its most recent filing with the SEC.
Vitae Pharmaceuticals (NASDAQ:VTAE) traded up 2.31% during trading on Monday, reaching $4.88. 573,488 shares of the company’s stock were exchanged. The firm’s market cap is $106.73 million. The stock’s 50 day moving average price is $8.57 and its 200 day moving average price is $12.03. Vitae Pharmaceuticals has a 52-week low of $4.15 and a 52-week high of $18.71.
Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.10. The company earned $0.09 million during the quarter, compared to the consensus estimate of $0.14 million. Vitae Pharmaceuticals’s revenue for the quarter was down 42.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) earnings per share. Equities research analysts anticipate that Vitae Pharmaceuticals will post ($2.23) EPS for the current fiscal year.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
(1)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼